Items tagged with Vaccines
Results from innovative Phase 2 tuberculosis vaccine trial offer potential for new BCG revaccination strategies, hope for subunit vaccines
A publication in F1000Research reviews the progress and challenges in TB vaccine development. "A new TB vaccine is... an inevitability; the question is how long will it take us to get there?"
The 5th Global Forum on TB Vaccines commenced today (February 20) in New Delhi. The Forum is a scientific conference, which provides a platform for researchers, clinicians, product developers, policymakers, advocates, and other stakeholders, to review the state of the field, share the latest research and findings with the end goal of developing new TB vaccines. Experts agreed that there is an urgent need to develop an effective vaccine against both drug-sensitive and drug-resistant (Multi-Drug Resistant and Totally Drug Resistant) TB. The target set forth in the WHO End TB Strategy to end the TB epidemic by 2035 cannot be achieved without new vaccines, as well as improved diagnostics and treatment. The Inaugural Ceremony was attended by the Minister of State for Health and Family Welfare, Ms. Anupriya Patel; Deputy Director General (Programmes), World Health Organization, Dr Soumya Swaminathan; Secretary, Department of Biotechnology, Dr Ashutosh Sharma; Secretary, Ministry of Health and Family Welfare, Ms Preeti Sudan; and other key dignitaries.
Our buses and trains are overcrowded not just in peak hours but almost all the time, making you wonder where all these people are heading to. But so are our malls. And our slums.
New live attenuated TB vaccine is safe and shows a distinct, dose dependent immune response in a Phase 1b trial in newborns (post)
Biofabri, the University of Zaragoza, the South African Tuberculosis Vaccine Initiative (SATVI) and TB Vaccine Initiative (TBVI) announced the results of a Phase 1b trial of the new live attenuated TB vaccine ‘MTBVAC’ at the 5th Global Forum on TB vaccines, held on 20-23 February 2018 in New Delhi, India.
With upwards of 2 billion individuals infected with Mycobacterium tuberculosis (Mtb) each year, the infection continues to pose a serious challenge on a global scale. Although advances have been made in the fight against the disease, much is left to be desired when it comes to diagnostic, treatment, and prevention options.
Tuberculosis remains the most deadly infectious diseases in the world. In particular, the growing number of multiresistant microbes is a cause of great concern to doctors and healthcare policymakers. At least a dozen candidate vaccines are currently undergoing clinical testing. One of them, VPM1002, has now been approved for use in a clinical efficacy trial. The trial is designed to test the vaccine’s efficacy and safety in patients in whom tuberculosis resurfaces following successful drug therapy. In addition, a phase II trial on newborns exposed to HIV has been completed with promising results.
A new study by Cornell College of Veterinary Medicine scientists unveils a novel approach to vaccine development in the fight against tuberculosis, illustrating how certain host cells are able to either control or promote the growth of the Mycobacterium tuberculosis (Mtb) bacterium.
New research in mice suggests that chronic infection with intestinal worms indirectly reduces the number of cells in lymph nodes near the skin, inhibiting the immune system's response to the Bacille Calmette-Guerin (BCG) vaccine for tuberculosis. Xiaogang Feng of Karolinska Institutet in Stockholm, Sweden, and colleagues present these findings in PLOS Pathogens.
WASHINGTON — Children exposed to anti-TNF alpha in utero do not have a higher risk for developing tuberculosis following a Bacillus Calmette-Guerin vaccination, according to research presented at Digestive Disease Week.
Page 10 of 12 · Total posts: 0←First 9 10 11 Last→